Risks and non-GAAP disclosures This presentation contains forward-looking statements within the meaning of U.S. securities laws, including statements related to our future financial results and our guidance for future financial performance (including expected revenues, operating income, margins and earnings per share). These forward-looking statements are based on current expectations, forecasts and assumptions involving risks and uncertainties that could cause the actual outcomes and results to differ mate ...

Group 1 - Cardinal Health, Inc. (NYSE:CAH) is recognized as one of the 15 Best Stocks to Buy for the Long Term [1] - Barclays initiated coverage on Cardinal Health with an Overweight rating and a price target of $243, expressing optimism particularly about drug distributors within the US healthcare technology and distribution space [2] - The stock has increased nearly 68% since the beginning of 2025, reflecting the company's transformation towards higher-margin areas, especially in specialty pharmaceuticals and managed services [3] Group 2 - In fiscal Q1 2026, Cardinal Health's revenue from the Pharmaceutical and Specialty Solutions segment rose 23% to $59.2 billion, driven by strong brand and specialty drug sales [3] - Total revenue for the quarter reached $64 billion, marking a 22% increase from the previous year, and the company completed the acquisition of Solaris Health, enhancing its scale in the urology sector [4] - Cardinal Health is one of the largest healthcare services and products companies in the US, supplying pharmaceuticals and medical equipment to a diverse range of providers [5]

Financial Performance & Guidance - NN's Q1 2025 net sales were $105.7 million, flat year-over-year on a pro forma basis, but down $15.5 million as reported[14, 40] - Adjusted EBITDA for Q1 2025 was $10.6 million, with an adjusted EBITDA margin of 10.0%, reconfirming FY 2025 guidance of $53-$63 million[14] - The company is lowering its 2025 net sales guidance to $430-$460 million due to GDP uncertainties, but reiterating adjusted EBITDA guidance of $53-$63 million and new business awards guidance of $60-$70 million[12] - NN initiates 2025 guidance for free cash flow at $14 to $16 million[12] Business Transformation & New Business - NN is launching 120 new programs in 2025, expected to add approximately $55 million in peak annual sales[11] - The company's new business program has secured $160 million of new business from January 2023 to May YTD 2025[16, 18, 21] - NN Europe achieved $6.7 million in new wins in Q1 2025, with an estimated total program value of over $50 million[25] - The company's working capital has been reduced by 20%, or $21.6 million, over the last two years, from $106.4 million in Q1 2023 to $84.8 million in Q1 2025[37, 38] Cost Reduction & Operational Efficiency - NN has reduced its global staff by 16%, or 525 people, over two years, with further reductions planned for 2025[29, 33] - The company is implementing a $6.5 million payroll reduction plan in 2025[33] - NN is advancing its organic transition into non-auto areas by leveraging $340 million of installed assets and investing $10-$14 million additional cash capex per year[12]